Trials & R&D · first seen 1h ago, updated 1h ago
Theialife’s race to bring a childhood myopia treatment to market
Our guest today is Thomas Ruggia, CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. The post Theialife’s race to bring a childhood myopia treatment to market a…
Summary from Labiotech.